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1. Introduction 
Metabolism is the process of making energy and cellular molecules from breaking down the 
food that made up of proteins, carbohydrates and fats etc. A metabolic disorder occurs 
when abnormal chemical reactions disrupt this process. When this happens, our body might 
have too much of some substances or too little of other ones that we need to stay healthy. 
Metabolic syndrome, a combination of several metabolic risk factors including abdominal 
obesity, insulin resistance, hypertension, and atherogenic dyslipidemia, is one of the most 
common health problems in the modern society. Increasingly accumulated evidence from 
epidemiologic and basic research data, as well as translational, clinical, and intervention 
studies suggested that metabolic syndrome may be an important etiologic factor for the 
onset of cancer. In fact cancer has long been indicated as a metabolic disease due to aberrant 
energy metabolism caused by mitochondrial damage.  
In living cells, processes of carbohydrate metabolism, lipid metabolism and energy 
metabolism are closely related. Metabolic syndrome (MS), such as diabetes, obesity, 
hyperlipidimia, and hypertension, is, more or less, associated with abnormal lipid 
metabolism. As a metabolic disease, cancer is caused by impaired energy metabolism due to 
impaired mitochondrial function, which is linked with abnormal mitochondrial membrane 
lipids, especially cardiolipin content [1]. Recent studies have indicated that abnormalities in 
cellular lipid metabolism are involved in both pathogenesis of metabolic syndrome and 
various cancers [2, 3]. 
As the major component of membranes and energy resources, cellular lipids, including 
phospholipids and neutral lipids (mainly triacylglycerols and sterol esters), play a crucial 
role for both cellular and physiological energy homeostasis. As cellular membrane structure 
components, phospholipids are important for cellular membrane remodeling and cellular 
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proliferation. Disruption of phospholipid homeostasis may lead to carcinogenesis and MS 
[4, 5]. Triacylglycerol, as an important energy storage form, is closely related to glucose 
homeostasis and its disregulation is associated with onset of MS such as diabetes, obesity, 
and cardiovascular diseases [6].  
In this chapter, we focused on the metabolism of phospholipid and triacylglycerol 
(including fatty acids) and discussed the association of lipid metabolism disorders with 
pathogenesis of MS and cancer as shown in Figure1. We also discussed the emerging role of 
omega-3 polyunsaturated fatty acids in preventing lipid disorder associated MS and cancer.  
 
Figure 1. Inter-relationship between lipid metabolism, metabolic syndrome and cancer  
2. Dietary lipids and metabolic diseases 
2.1. Dietary lipids and metabolic syndrome  
MS, also known as syndrome X, or the insulin resistance syndrome, is a combination of 
medical disorders comprising an array of metabolic risk factors including central obesity, 
dyslipidemia, hypertension, glucose intolerance, and insulin resistance[7]. The worldwide 
prevalence of MS causes lots of health problems not only in the developed countries, but 
also in the developing countries as well. Individuals with MS are at high risk for diabetes 
and cardiovascular disease. Increasingly accumulated evidence shows that aberrations in 
lipid metabolism are the central to the etiology of MS. 
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As one of the most abundant lipid species and major components of very-low-density 
lipoprotein (VLDL) and chylomicrons, triacylglycerols (TAG) play an important role in 
metabolism as energy sources. It can be acquired from de novo synthesis in liver or dietary 
lipids. Depending on the oil source, TAGs are either the main constituents of vegetable oils 
(typically more unsaturated) or animal fats (typically more saturated). Animal fat comprises 
about 40% of the energy intake in the human diet in Western countries, and a high 
proportion of this is TAG. Fat tissue, liver and intestine are the major places where TAG is 
synthesized and stored. There is also some intracellular storage of TAG e.g. in the muscle 
and brain cells. The storage of TAG can be replenished from dietary fat, or by endogenous 
synthesis of fat from carbohydrates or proteins, which mainly takes place in the liver. 
The overabundance of nutrients such as lipids in obesity and caloric surplus leads to 
aberrant lipid management and ectopic fat accumulation (i.e., ‘‘lipotoxicity’’), which is a 
fundamental component of metabolic disease and insulin resistance [8, 9]. 
2.1.1. Fatty acids and insulin resistance 
Insulin resistance is the center underlying the different metabolic abnormalities in the 
metabolic syndrome, in which pathophysiological conditions insulin becomes less effective 
in lowering blood glucose. Insulin resistance can be induced by various environmental 
factors, including dietary habits. Muscle, liver and fat are the three major tissues for 
maintaining blood glucose levels. In the presence of insulin, fat and muscle cells absorb 
glucose, and the liver regulates glucose levels by reducing its secretion and increasing its 
storage in the form of glycogen. However, in the condition of insulin resistance, glucose 
uptake by muscle and fat cells is disrupted, and glycogen synthesis and storage are also 
reduced in liver cells, resulting in failure of suppressing glucose production and releasing 
into the blood. Impaired glucose metabolism is associated with molecular alterations of 
insulin signaling, which is particularly well characterized in muscle [10]. 
Insulin also facilitates the uptake and storage of amino acids and fatty acids by converting 
them to protein and lipid, respectively. Besides the diminished glucose- lowering effects, 
insulin resistance also causes reduced actions of insulin on lipids and results in decreased 
uptake of circulating lipids and increased hydrolysis of stored triglycerides and, as a 
consequence, elevates free fatty acids in the blood plasma. Elevated levels of free fatty acids 
and triglycerides in the blood and tissues have been reported to contribute to impaired 
insulin sensitivity in many studies [11, 12]. Increased contents of fatty acids and their 
metabolites cause phosphorylation of insulin receptor substrate 1 (IRS-1) at serine, which 
blocks IRS-1 tyrosine phosphorylation and the associated activation of phosphatidylinositol- 
3' kinase (PI3K) activity, and results in a decreased translocation of the glucose transporter 
GLUT4 to membrane of muscle and liver cells [13, 14].  
The conversion of fatty acids to acetyl-CoA, the process known as β-oxidation, mainly 
occurs in the mitochondria. Defects in mitochondrial fatty acid oxidation and in adipocyte 
fat metabolism may increase fatty acid content in muscle and liver, which, in turn, cause 
impaired transport of glucose and defective glycogen synthesis in muscle, and sustained 
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output of glucose from the liver, which finally lead to hyperinsulinemia and insulin 
resistance. In addition, oxidative stress and cytokine induction in liver may lead to the 
development of nonalcoholic fatty liver (NAFLD). Considerable experimental evidence 
suggests that increased hepatic fat synthesis contributes to nonalcoholic steatohepatitis and 
associated insulin resistance [15]. 
Dietary fat composition is the major sources of free fatty acids in the blood and tissue. 
Consumption of high fat diets is strongly and positively associated with overweight that, in 
turn, deteriorates insulin sensitivity, particularly when the excess of body fat is located in 
abdominal region. Epidemiological evidence and experimental animal studies clearly show 
that saturated fat significantly worsen insulin resistance, while monounsaturated (MUFA) 
and polyunsaturated fatty acids (PUFA) improve it through modifications in the 
composition of cell membranes, and an elevated ratio of saturated fats to unsaturated fats is 
a risk factor for MS [16, 17]. 
A multicenter study has shown that shifting from a diet rich in saturated fatty acids (SFAs) 
to one rich in monounsaturated fat improves insulin sensitivity in healthy people [18]. 
Substitution of unsaturated fat for saturated fat reduces both LDL cholesterol and plasma 
triglycerides in insulin resistant individuals [16]. Several early cross- sectional studies have 
found a positive association between saturated fat intake and hyperinsulinaemia, and 
insulin resistance [19, 20], while polyunsaturated fat intake was inversely associated with 
plasma insulin levels whereas linoleic acid intake was positively associated with fasting 
plasma insulin concentrations, and increased unsaturated fat intake is associated with 
improved insulin sensitivity [16, 21]. 
In addition, numerous observations in rodent and cell culture models as well as obese and 
diabetic humans have shown that chronic lipid exposure is associated with insulin 
resistance [22-24], and fatty acid composition in body tissues is related to the incidence of 
diabetes [25]. Particular, intramuscular or hepatic content of TAG, diacylglycerol (DAG), or 
ceramide is negatively correlated with insulin sensitivity [26-28], which may be caused by 
disrupted insulin-stimulated translocation of the GLUT4 by ectopic accumulation of TAG 
and other lipid molecules in liver and muscle. 
More and more evidence suggests that ceramide, composition of sphingosine and fatty acid 
and found in high concentrations within the cell membrane, plays a critical role in insulin 
resistance [29]. Both in vitro and in vivo studies have produced a large body of data 
implicating that accumulation of ceramide and its metabolites is associated with nutrient-
induced pathogenesis of insulin resistance and metabolic diseases, including diabetes, 
cardiomyopathy, and atherosclerosis [28-30]. In cultured cells, ceramide inhibits insulin- 
stimulated glucose uptake by blocking translocation of the glucose transporter GLUT4, and 
glycogen synthesis [31, 32]. These effects are due to the ability of ceramide to block 
activation of Akt/PKB, a serine/threonine kinase that is activated by insulin and growth-
factors. It is also found that accumulation of ceramide may impair mitochondrial function 
by altering mitochondrial membrane permeability, inhibiting electron transport chain 
intermediates, and promoting oxidative stress [33]. 
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In rodents, inhibition of ceramide de novo synthesis pathway by serine palmitoyltransferase 
inhibitor myriocin improves insulin sensitivity and prevents insulin resistance associated 
metabolic diseases [30, 34-36]. In humans, it is well documented the association of ceramides 
accumulation in peripheral tissues, including muscle and fat, of obese subjects with insulin 
resistance [37-40]. 
2.1.2. Fatty acids and cardiovascular diseases 
Since the 1950s, it has long been believed that consumption of foods containing high amounts 
of SFAs, including meat fats, milk fat, butter, lard, coconut oil, etc, is not only a risk factor for 
dyslipidemia and insulin resistance, but also a risk factor for cardiovascular diseases. 
However, recent evidence from systematic reviews, meta-analyses and prospective cohort 
studies indicates that SFAs alone maybe not associated with an increased risk of 
cardiovascular disease. A randomized controlled dietary intervention trial that compared a 
carbohydrate restricted diet to a low fat diet over a 12-week period in overweight subjects with 
atherogenic dyslipidemia found that carbohydrate restriction, rather than a low fat diet may 
improve features of MS and cardiovascular risk [41]. In a recent cross-sectional study 
conducted in Japanese to exam the relationship between dietary ratio of PUFA to SFA with 
cardiovascular risk factors and MS, the data showed that dietary polyunsaturated to saturated 
fatty acid ratio was significantly and inversely related to serum total and LDL cholesterol, but 
did not significantly relate to single metabolic risk factors or the prevalence of MS [42].  
However, on the other hand, some SFAs such as stearic acid and fatty acids found in milk 
and milk products appear to be beneficial and may diminish the risk for cardiovascular 
disease. In a systematic review, after comparing with those of trans, other saturated, and 
unsaturated fatty acids (USFAs), Hunter et al [43] found that stearic acid raised LDL 
cholesterol, and compared with USFA, stearic acid lowered HDL cholesterol and increased 
the total cholesterol/HDL cholesterol ratio [43].  
Palmitoleic acid (cis-16:1, n-7) has been linked to both beneficial metabolic effects. It has 
been reported that adipose-produced cis-palmitoleate directly improved hepatic and 
skeletal muscle insulin resistance and related metabolic abnormalities, and suppressed 
hepatic fat synthesis as well [44]. A prospective cohort study showed that circulating trans-
palmitoleate (trans-16:1, n-7) is associated with lower insulin resistance, decreased presence 
of atherogenic dyslipidemia, and incidence of diabetes incidence [45] suggesting metabolic 
benefits of dairy consumption. There is also strong evidence collected by systematic review 
and meta-analysis of randomized controlled trials showing that consumption of 
polyunsaturated fat as a replacement for saturated fat alleviates coronary heart disease risk 
[46]. While many studies have found that replacement of saturated fats with 
polyunsaturated fats in the diet produces more beneficial outcomes on cardiovascular health 
[47, 48], the effects of substituting monounsaturated fats or carbohydrates are still unclear. 
2.1.3. Omega-3 PUFAs and metabolic syndrome      
Omega-3 PUFAs (also called ω−3 fatty acids or n−3 fatty acids are commonly found in 
marine and plant oils, which contain a double bond at the third carbon atom from the 
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methyl-end of the carbon chain. These PUFAs, including α-linolenic acid (ALA, 18:3, n-3), 
eicosapentaenoic acid (EPA, 20:5, n−3) and docosahexaenoic acid (DHA, 22:6, n−3), are 
considered as essential fatty acids because they can not be de novo synthesized by the 
human body. In human diets, ALA is usually derived from botanical sources such as perilla, 
flaxseed, canola, rapeseed, soybean, linseed and walnut. EPA and DHA are found in fish 
and some other sea foods [49]. Recent researches have shown that, while diets rich in 
saturated fatty acids (SFAs) are associated with an increased prevalence of obesity and type 
2 diabetes, supplement of omega-3 PUFAs rich in eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) has anti-inflammatory and anti-obesity effects and protect 
against metabolic abnormalities [50].  
Earlier epidemiologic observations showed the beneficial properties of n-3 PUFAs in 
populations consuming large amounts of fatty fish and marine mammal oils [51]. Later 
studies showed that a 3-wk supplement with fish oil rich in n-3 PUFA in healthy humans 
resulted in improved sensitivity to insulin, higher fat oxidation, and increased glycogen 
storage [52]. Most subsequent studies confirmed these effects and observed that 
supplementation with n-3 PUFAs, either EPA or DHA alone, or with their combination in 
fish oil, has favorably effects on many adverse serum and tissue lipid alterations related to 
the metabolic syndrome by reducing levels of fasting and postprandial serum 
triacylglycerols and free fatty acids [53, 54]. Some of the effects of n-3 PUFAs on lipid and 
lipoprotein metabolism could remain in subjects who become overtly diabetic. 
In addition, other recognized benefits of n-3 PUFAs include a reduction in inflammatory status, 
decreased platelet activation, mild reduction in blood pressure, improved endothelial function, 
and increased cellular antioxidant defense, all of which may prove particularly favorable in 
overweight, hypertensive patients [55]. Furthermore, supplementation with fish oil also blunted 
the sympathetic activity elicited by mental stress in healthy volunteers [56]. However, the 
beneficiary effects of n-3 PUFA supplementation on cardiovascular risk prevention are 
association with other components of lifestyle, ie, weight control, regular physical activity, and 
consumption of other dietary ingredients contributing to risk reduction [57]. 
The mechanisms underlying beneficiary effects of use n-3 PUFAs/fish oils or a combination 
of EPA and DHA have been extensively analyzed. Studies in animal and humans have 
demonstrated that, in addition to be used as fuels and structural components of the cell, the 
dietary intake of marine fish oil is also effective in lowering both triglyceride (Tg) and 
VLDL-Tg concentration in experimental animals and normal and hyper- triglyceridemic 
men [58, 59], which might be related to decreased mRNA encoding several proteins 
involved in hepatic lipogenesis including SREBP1, and enhanced fatty acid oxidation 
throughout a peroxisome proliferator- activated receptors (PPARs)—stimulated process [60, 
61]. Moreover, n-3 PUFAs elevate the fatty acid composition of membrane phospholipids 
that modify membrane-mediated processes such as insulin transduction signals, activities of 
lipases and biosynthesis of eicosanoids [62].  
Furthermore, dietary fish oil consumption normalizes the function of many tissues or cells 
involved in insulin sensitivity in the sucrose-rich diet (SRD) fed rats. It reverses 
dyslipidemia and improves insulin action and adiposity by reducing adipocytes cell size, 
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increasing insulin sensitive and decreasing the release of fatty acids. Both oxidative and 
non-oxidative glucose pathways are improved in muscle. In isolated beta cells, lipid 
contents and glucose oxidation return to normal [63]. All these effects lead to the 
improvement of glucose- stimulated insulin secretion and muscle insulin insensitivity. 
Adipose tissue plays a key role in the development of MetS and improvement of adipose tissue 
function is specifically linked to the beneficial effects of n-3 PUFA [64]. In accordance with the 
general anti-inflammatory action, n-3 PUFA supplementation induces production and secretion 
of adiponectin [65], the major adipokine exerting an insulin-sensitizing effect, and prevents 
adipose tissue hyperplasia and hypertrophy, and induces mitochondrial biogenesis in 
adipocytes [66], which effects maybe mediated by n-3 PUFA induced AMP-activated protein 
kinase (AMPK), a metabolic sensor controlling intracellular metabolic fluxes [64]. 
2.2. Dietary lipids and cancer 
Case–control and cohort studies have found positive associations between several cancers 
such as prostate cancer[67], ovarian cancer[68], breast cancer[69], colon cancer[70] etc, and 
an intake of foods with high levels of saturated fats, such as red meat, eggs, and dairy 
products. However, controversial results have also been reported about the role of high fat 
diet in carcinogenicity [71, 72]. This is largely due to the complexity of the diet, not only the 
fat components such as SFA, MUFA, and PUFA may vary among people in different 
regions, but also other non-fat nutrients may also alter the function of fat. Therefore only 
preclinical animal studies with clearly-defined fat composition may help elucidate the 
causal relationship between dietary fat and cancer. Up to now, it is generally accepted that 
cis-MUFA and omega-3 PUFAs are inversely associated with the increased risk of cancer, 
while SFA and omega-6 PUFAs are associated with the development of cancer [73]. 
However, physiologically, the metabolism of fatty acids are connected, any results based on 
a single fatty acids may be incomprehensive, therefore a fat containing diet with elevated 
MUFA and low ratio of omega-6/omega-3 fatty acid is suggested to be associated with 
cancer prevention and protection [74]. Interested readers are advised to read recent review 
articles about the association of dietary lipids with prostate [75] and breast cancer [76], and 
potential mechanisms for the association of dietary lipids with cancer [77-79]. 
2.2.1. Saturated fatty acids 
Recent studies have shown that high fat diet with saturated animal fat as major fat in the 
diet is associated with several cancer such as prostate cancer [67], colon cancer [80], ovarian 
cancer [68] and breast cancer [81] etc, whereas high fat diet with plant oils is not associated 
with cancer risk, however this may not be true, plant oils high in omega-6 fatty acids may be 
risk factors for cancer, which will be discussed in the polyunsaturated fatty acid section.  
2.2.2. Monounsaturated fatty acids 
It has been found that cancer incidence in the Mediterranean countries, where the main 
source of fat is olive oil, is lower than in other areas of the world. Such effects may be due to 
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the main MUFA in olive oil, oleic acid, and to certain minor compounds such as squalene 
and phenolic compounds [82]. Recent studies have also shown that canola oil, with high 
MUFA, oleic acid, can decrease colon and breast cancer incidence significantly [83, 84]. 
Although the authors suggested that such effect may be caused by omega-3 fatty acids, 
ALA, as high as 10% in canola oil, however, the role of oleic acid, as high as 61% in canola 
oil, cannot be excluded. So far, no epidemiological studies or animal studies can clearly 
demonstrate the preventive effect of MUFA on cancer, However, in vivo analysis of the fatty 
acid composition of the adipose tissue of breast cancer and healthy women showed that 
elevated adipose MUFA, oleic acid, are associated with reduced odds of breast cancer 
[85]. Although the mechanism underling the protective function of oleic acid on cancer is, so 
far, not clear, it has been found that oleic acid, when complexed with the molten globule 
form of alpha-lactalbumin (α-LA), acquires tumoricidal activity [86]. Carrillo et al found that 
oleic acid can inhibit store-operated Ca(2+) entry (SOCE), a Ca(2+) influx pathway, involved 
in the control of multiple cellular and physiological processes including cell proliferation, 
thus regulating the growth of colon carcinoma cells [87]. 
2.2.3. Polyunsaturated fatty acids 
Increasing evidences from animal and in vitro studies indicate that populations who ingest 
high amounts of omega-3 fatty acids in their diets have lower incidences of breast, colon, 
and, perhaps, prostate cancers. Paola et al. [88] used MTT viability test and expression of 
apoptotic markers to evaluate the effect of PUFAs on cancer growth, and their results 
indicated that EPA and DHA might induce modifications of tumor cell membrane structure 
leading to an obviously decreased induction rate of breast cancer. Menéndez et al. [89] also 
reported that omega-3 PUFAs ALA suppresses the overexpression of HER2, which plays an 
important role in aetiology, progression and chemosensitivity of various types of human 
cancers, suggesting that ALA is a potential anticancer agent. However, the clinical roles of 
omega-3 PUFAs may rely not only on the absolute content but also on the proportion of 
omega-3 PUFAs to omega-6 PUFAs in the cells due to the inverse biological functions of 
these two series of PUFAs. A higher omega-6/omega-3 PUFAs ratio contributes to many 
diseases including cancer, cardiovascular and inflammation. Reducing the omega-6/omega-
3 PUFAs ratio can help lower the risk of initiation and development of cancer. Berquin et al. 
established a prostate-specific phosphatase and tension homolog (PTEN) knockout mouse 
model, and the result demonstrated that a dietary ratio of omega-6/omega-3 PUFA lower 
than 5 was effective in suppressing tumor growth, and extending animal lifespan [90] The 
recent research suggested that a balanced ratio of omega-6/omega-3 PUFAs (1:1) exerts a 
beneficial effects on cell function and physiology [91]. 
2.2.4. Potential mechanisms of the association of dietary lipids with cancer 
Although it has been generally accepted that dietary lipids are associated with 
carcinogenesis and the development of cancer, the detailed mechanism is still far from clear. 
When lipids are digested and absorbed by small intestine mucosa cells, they can be 
transported to adipocytes for storage, or used for energy production by peripheral cells 
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through fatty acid β-oxidation. They can also be used for membrane lipid biosynthesis. 
Upon environmental stimulus, these lipids may be hydrolyzed and free fatty acids are 
released. Omega-6 PUFAs such as ARA released from membrane lipids will be converted to 
normal eicosanoids, and regulate cellular physiology; however elevated levels of these 
eicosanoids may accelerate cell proliferation and lead to inflammation and carcinogenesis, 
etc [92]. Whereas omega-3 PUFAs such as EPA, when released from membrane lipids, may 
be converted to eicosanoids with opposite activity to the product of omega-6 fatty acids, 
which inhibit cell proliferation and COX-2 activity, thus providing cancer preventive 
function [93]. Another mechanism of regulation of cancer initiation and development may 
be elucidated by fatty acid signaling pathway through its receptors. In particular, two 
transcription factors, sterol regulatory element binding protein-1c (SREBP-1c) and 
peroxisome proliferator activated receptor alpha (PPAR alpha), have emerged as key 
mediators of gene regulation by FA [94, 95]. SREBP-1c induces a set of lipogenic enzymes in 
liver. PUFA, but not SFA or MUFA, suppressES the induction of lipogenic genes by 
inhibiting the expression and processing of SREBP-1c. Thus inhibits the de novo lipogenesis 
of fatty acids, which is of particular importance for cancer cells [96].  
PPAR alpha plays an essential role in metabolic adaptation to fasting by inducing the genes 
for mitochondrial and peroxisomal FA oxidation as well as those for ketogenesis in 
mitochondria. FAs released from adipose tissue during fasting are considered as ligands of 
PPAR alpha. Dietary PUFA, except for 18:2 n-6, are likely to induce FA oxidation enzymes 
via PPAR alpha as a "feed-forward " mechanism. PPAR alpha is also required for regulating 
the synthesis of highly unsaturated FA, indicating pleiotropic functions of PPAR alpha in 
the regulation of lipid metabolic pathways. Thus, in addition to its inhibition of fatty acid 
biosynthesis through SREBP, omega-3 fatty acids induce fatty acid degradation through 
PPAR alpha, in so doing, they regulate fatty acid metabolism and metabolic diseases. 
Multiple mechanisms of omega-3 fatty acids mediated inhibition of cancer may include 
suppression of neoplastic transformation and cell growth, and enhanced apoptosis and 
antiangiogenicity etc [97].  
3. De novo lipogenesis in metabolic disease 
3.1. De novo lipogenesis in metabolic syndrome 
De novo fatty acid biosynthesis occurs in essentially all cells, but adipose tissue and liver are 
the major sites. The first committed step in fatty acid synthesis is catalyzed by fatty acid 
synthase (FAS), a multifunctional cytosolic protein that primarily synthesizes palmitate. 
Variations in FAS expression and enzyme activity have been implicated in insulin resistance 
and obesity in humans [98]. A circulating form of FAS has been reported as a biomarker of 
metabolic stress and insulin sensitivity. In humans it changes with weight loss and may 
reflect improved insulin sensitivity [99]. 
Fatty acid elongation is catalyzed by Elovl (elongation of very long-chain fatty acid) 
proteins. Elovl6 is thought to be involved in de novo lipogenesis and is regulated by dietary, 
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hormonal and developmental factors. Mice with Elov6 deficiency are obese but protected 
from insulin resistance [100, 101].  
Citrate produced by the tricarboxylic acid cycle in mitochondria is converted by ATP-citrate 
lyase (ACL) to acetyl-CoA, which is next converted to malonyl-CoA by acetyl CoA 
carboxylase (ACC). Malonyl-CoA is a potent inhibitor of carnitine- palmitoyl transferase 1 
(CPT1), which transports FAs into the mitochondria for oxidation, thus plays a key role in the 
regulation of both mitochondrial fatty acid oxidation and fat synthesis. ACC catalyzes a key 
rate-controlling step in both de novo lipogenesis and fatty acid oxidation. The absence of ACC 
decreases the cellular concentration of malonyl-CoA, removes the inhibition of CPT1 and 
maintains FA oxidation. In rats with NAFLD, suppression or knockdown of ACC isoforms 
significantly reduced hepatic malonyl-CoA levels, lowered hepatic lipids including long-chain 
acyl-CoAs, DAG, and triglycerides, and improved hepatic insulin sensitivity [102].  
Lipogenesis and FA oxidation are highly integrated processes. Studies in genetically 
modified mice have demonstrated that inhibition of FA synthesis and storage is associated 
with upregulation of FA oxidation [103]. For examples, knockout the diacylglycerol 
acyltransferase (DGAT), an enzyme that catalyses the final acylation step of TAG synthesis, 
reduced fat deposition and protected mice against diet- induced obesity and, in the 
meanwhile, elevated mice energy expenditure and increased activity, suggesting a 
correlation of disrupted FA storage and increased FA oxidation [104, 105]. Similarly, 
deletion of acetyl-CoA carboxylase 2 (ACC2), an isoform of ACC and key enzyme for de 
novo FA synthesis, leads to a lean mouse with increased FA oxidation [106].  
As a major component of the metabolic syndrome, NAFLD characterizes with the 
accumulation of TAGs in hepatocytes, and development of steatohepatitis, cirrhosis, and 
hepatocellular carcinoma. FAs stored in adipose tissue and newly made through liver de 
novo lipogenesis are the major sources of TAGs in the liver [107]. 
Lipogenesis is also an insulin- and glucose-dependent process that is under the control of 
specific transcription factors. SREBP1 is such a transcription factor and activates most genes 
involved in FA synthesis. It occurs in two isoforms, SREBP1a and 1c, through alternative 
splicing. SREBP-1c is highly expressed in the WAT, liver, adrenal gland, brain, and muscle and 
regulates the expression of many of the genes involved in de novo FA and TAG synthesis 
including ACC and FAS [108, 109]. Insulin increases lipogenesis through activating SREBP-1c 
that is dependent on the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) [110]. 
SREBP1 gene expression is decreased in adipose tissue of obese subjects and the aberrant 
activation of SREBPs may contribute to obesity-related pathophysiology in various organs, 
including cardiac arrhythmogenesis and hepatic insulin resistance. 
Lipogenesis is also regulated by glucose activated carbohydrate response element-binding 
protein (ChREBP), which induces gene expression of liver-type pyruvate kinase, a key 
regulatory enzyme in glycolysis; this enzyme in turn provides the precursors for lipogenesis 
[111]. ChREBP also stimulates expression of genes involved in lipogenesis [112] including 
SREBP-1c, which in turn activates glycolytic gene expression, promoting glucose 
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metabolism, and lipogenic genes in conjunction with ChREBP [113]. ChREBP knockout mice 
show decreased liver triglyceride but increased liver glycogen content indicating that 
ChREBP may regulate metabolic gene expression to convert excess carbohydrate into 
triglyceride rather than glycogen [114]. In addition, complete inhibition of ChREBP in ob/ob 
mice reduces the effects of the MS such as obesity, fatty liver, and glucose intolerance, 
indicating it as a potential target for treatment of MS [115]. 
3.2. De novo lipogenesis in cancer 
Enhanced flux of glucose derivatives through glycolysis, which sustain the redirection of 
mitochondrial ATP to glucose phosphorylation, and de novo FA synthesis is a hallmark of 
aggressive cancers. Although most normal cells use FA from dietary lipids, tumor cells de 
novo synthesize more than 95% of lipids required for cell proliferation despite having 
enough nutritional supply of lipids. Lipogenic enzymes such as, FAS, ACC, and ACL 
involved in FA biosynthesis, glycerol-3-phosphate dehydrogenase involved in lipid 
biosynthesiss, and SREBP1, the master regulator of lipogenic gene expression, are found to 
be overexpressed in a number of cancer or cancer cells, such as prostate cancer [116], ovarian 
cancer [117], breast cancer [118], lung cancer [119], colon cancer [120], and etc. Some 
research has been carried out to provide insights into the molecular mechanism of the 
association of lipogenesis and cancer. In this chapter we focused on three main lipogenic 
genes: FAS, ACC, and ACL. 
3.2.1. Fatty acid synthase 
High levels of FAS expression have been found in many human cancers, including  prostate 
cancer [121], ovarian cancer [117, 122], breast cancer [123], bladder cancer [124], colon cancer 
[125] mantle cell lymphoma [126], and etc. However, the cellular mechanism by which FAS 
is up-regulated in cancer cells is not fully understood. Nevertheless a few studies suggested 
that steroid hormones and human epidermal growth factor receptor (HER) family ligands, 
especially HER2 could increase FAS expression via the PI3K/Akt or mitogen-activated 
protein kinases (MAPK) pathways[117]. Recently Mukherjee et al [117] demonstrated that 
bioactive lipid lysophosphatidic acid (LPA) induces FAS expression and lipogenesis 
through LPA2-G12/13-Rho-SREBP signaling pathway in ovarian cancer cells. Moreover 
over-expression of FAS in non-cancerous epithelial cells is sufficient to induce a cancer-like 
phenotype through the induction of HER1/HER2 [127], therefore FAS over-expression may 
play a role in carcinogenesis. Furthermore FAS overexpression is found to be associated 
with the advanced stage of colorectal cancer and liver metastasis, thus it may also play a role 
in the progression of cancer [128]. So far abundant evidences have shown that FAS 
contributes to both tumorigenesis and metastasis, and it becomes an ideal target for cancer 
therapy. In deed inhibition of FAS activity by FAS specific inhibitors or siRNA can 
significantly inhibit cancer or cancer cell growth, induce cancer cell apoptosis, and reduce 
the metastasis of several cancers[124, 129]. Both synthetic chemicals and natural products of 
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FAS inhibitors have been developed [123[130], and the recent progress in developing FAS 
inhibitors as cancer drugs has been reviewed by Pandey et al [131].  
3.2.2. ATP-Citrate lyase and acetyl CoA carboxylase  
Apart from FAS, other key lipogenic enzymes for de novo FA biosynthesis include ACL and 
ACC. While ACL produce the substrate acetyl-CoA from glycolytic product citrate, ACC 
activates the substrate to generate malanyl-CoA, the building block for fatty acid synthesis. 
Both ACC and ACL have been found to be over-expressed in many cancers such as breast, 
liver, lung, ovarian, prostate and leukemia cancers [132, 133]. Inhibition of either ACL or 
ACC induces growth arrest and apoptosis in several cancer cell lines [134-136]. The potential 
mechanism of ACL overexpression in tumorigenesis is through PI3K/AKT and MAPK 
signaling pathway [135, 137]. Yoon et al [138] found that the major mechanism of HER2-
mediated induction of ACC alpha in breast cancer cells is translational regulated primarily 
through mTOR signaling pathway. While Mukherjee et al [117] found that LPA induced 
induction of ACC in ovarian cancer cells is through LPA2-Gq-PLC-AMPK signaling 
pathway. Many small molecule inhibitors for ACL and ACC have been developed as 
potential therapeutic agents for cancer [133, 139]. 
4. Phospholipids metabolism in metabolic diseases 
Phospholipids are polar lipids as major component of membrane structure and some 
intracellular complex such as lipoproteins. Enzymes involved in the metabolism of 
phospholipids include phospholipase A2 (PLA2), phospholipase C (PLC), phospholipase D 
(PLD), and lysophospholipase D (autotoxin), and alterations of these enzymes have been 
found to be linked with metabolic diseases, such as MS and cancer. In addition, the 
intermediates or end products of phospholipid metabolism such as phosphatidic acid (PA), 
DAG, LPA, sphingosine-1-phoshate (S-1-P), and free fatty acid arichidonic acid (ARA), are 
also involved in the pathogenesis of metabolic diseases. 
4.1. Phospholipid metabolism in metabolic syndrome 
Phosphatidylcholine (PC) is the most abundant phospholipids in animal cells. Blocking S-
adenosylmethionine (SAMe) or PC synthesis in C. elegans, mouse liver, and human cells 
have been found to cause elevated SREBP-1-dependent transcription and lipid droplet 
accumulation [4], suggesting nutritional or genetic conditions limiting SAMe or PC 
production may activate SREBP-1, and contribute to human metabolic disorders. 
Phosphatidylethanolamine (PE) is another abundant phospholipid in mammals. PE and its 
downstream signaling events play an important role in the heart function, and alteration in 
the asymmetrical transbilayer distribution of PE in sarcolemmal membranes during 
ischemia causes sarcolemmal disruption [140]. Moreover, abnormalities in the molecular 
species profile of PE may contribute to membrane dysfunction and defective contractility of 
the diabetic heart [141, 142].  
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SREBPs may play critical roles in phospholipid homeostasis and lipotoxic cardiomyopathy. 
Dysregulated phospholipid signaling that alters SREBP activity has been reported to 
contribute to the progression of impaired heart function in flies and also act as a potential 
link to lipotoxic cardiac diseases in humans [143]. Thus the role of SREBPs in modulating 
heart function and its associated phospholipid signaling maybe a candidate target for future 
therapies for obesity- and diabetes- related cardiac dysfunction.  
4.2. Phospholipid metabolism in cancer 
An aberrant choline phospholipid metabolism is another major hallmark of cancer cells. In 
deed alterations of choline phospholipid metabolism have been reported in ovarian cancer 
and also in breast cancer [144, 145]. Altered choline phospholipid metabolism in ovarian 
cancer has been found to be linked with the regulation of FAS. Because the drop in the level 
of PC (59%) was significantly correlated with a drop in de novo synthesized FA levels, PC 
was identified as a potential noninvasive magnetic resonance spectroscopy–detectable 
biomarker of FAS inhibition in vivo [146]. Phospholipids and their metabolism have been 
found to be involved in ovarian cancer in several forms, including LPA, PLA2, PLD, and 
autotoxin (ATX). Although aberrant phospholipid metabolism has been found in other 
cancers, the most detailed research work has been carried out using ovarian cancer as a 
model, so in this section we summarized the recent advances in the research of 
phospholipid metabolism and ovarian cancer. 
4.2.1. Lysophosphatidic acid 
The LPAs, with their various FA side chains, are the constituents of a growth-stimulating 
factor—ovarian cancer activating factor—that has been identified from ascites in patients 
with ovarian cancer [147]. As a bioactive compound, LPA works to induce cell proliferation 
or differentiation, prevents apoptosis induced by environmental stress or stimuli, induce 
platelet aggregation and smooth muscle contraction, and stimulate morphological changes, 
adhesion and migration of cells. It thus is involved in a broad range of biologic processes in 
a variety of cellular systems [148, 149]. As an established mitogen, LPA also promotes the 
invasiveness of hepatoma cells into monolayers of mesothelial cells, and stimulates 
proliferation of ovarian and breast cancer cell lines even in the absence of other growth 
promoters such as serum. Furthermore, LPA stimulates rapid neurite retraction and 
rounding of the cell body in serum-deprived neuroblastoma cells [150], and plays a critical 
role in regulation of gene expression in normal and neoplastic cells. It is a potent modulator 
of the expression of genes involved in inflammation, angiogenesis, and carcinogenesis such 
as interleukin [151-154], vascular endothelial growth factor (VEGF) [155], urokinase 
plasminogen activator [156], and cyclooxygenase-2 [157]. Thus LPA may contribute to 
cancer progression by triggering expression of those target genes, resulting in a more 
invasive and metastatic microenvironment for tumor cells [152, 158]. A significant increase 
in the expression of LPA receptors (LPA2 and LPA3) with VEGF was found by Fujita et al. 
[159], who suggested that LPA receptors might be involved in VEGF expression mediated 
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by LPA signals in human ovarian oncogenesis. The recent identification of metabolizing 
enzymes that mediate the degradation and production of LPA and the development of 
receptor selective-analogs has opened a potential new approach to the treatment of ovarian 
cancer [160]. LPA also stimulates VEGF expression independent of hypoxia-inducible factor 
1 (H1F1) and promotes tumor angiogenesis by activation of c-Myc and Sp-1 transcription 
factors [161]. A very recent study shows that LPA induces de novo lipogenesis through 
LPA2-G12/13-SREBP-FAS, and LPA2-G(q)-AMPK-ACC signaling pathway. 
4.2.2. Phospholipase A2 
The PLA2 enzyme has been implicated in the activation of cell migration and the production 
of LPA in ovarian carcinoma cells [162]. Autonomous replication and growth-factor-
stimulated proliferation of ovarian cancer cells are highly sensitive to inhibition of calcium-
independent PLA2 (iPLA2), but are refractory to inhibition of cytosolic PLA2 [162]. 
Activation of iPLA2 plays a critical role in cell migration, which is involved in many 
important biologic processes such as development, the immunologic and inflammatory 
responses, and tumor biology [162]. When ovarian cancer cells were grown under growth-
factor-independent conditions, suppression of iPLA2 activity led to an accumulation of cell 
populations in both the S and the G2/M-phases [163]. Supplementation with exogenous 
growth factors such as LPA and epidermal growth factor in culture released the S-phase 
arrest, but did not affect the G2/M arrest associated with inhibition of iPLA2. In addition to 
the prominent effect on the cell cycle, inhibition of iPLA2 also induced weak-to-modest 
increases in apoptosis [163]. Downregulation of iPLA2 with lentivirus-mediated RNA 
interference targeting iPLA2 expression inhibited cell proliferation in culture and decreased 
tumorigenicity of ovarian cancer cell lines in athymic nude mice [163]. Recently iPLA2 has 
been found to play a role in breast cancer metastasis as iPLA2 deficiency protects breast 
cancer from metastasis to the lung [164]. 
4.2.3. Phospholipase D 
PLD, a family of signaling enzymes that most commonly responsible to generate most lipid 
second messenger phosphatidic acid (PA), is found in diverse organisms from bacteria to 
humans and functions in multiple cellular pathways. It has been increasingly recognized as 
a critical regulator of cell proliferation and tumorigenesis and the expression and activity of 
PLD are elevated in many different types of human cancers.  
In ovarian cancer cells, PLD is involved in the formation of PA, which may be further 
converted to LPA by PLA2. It was suggested that PLD is also involved in cancer progression 
and metastasis and elevated PLD expression has been reported in various cancer tissues 
[165]. Moreover, PLD was found to stimulate cell protrusions in v-Src–transformed cells 
[166]. Furthermore, PLD activity was elevated by the integrin receptor signaling pathway in 
OVCAR-3 cells, and PLD blocking was found to inhibit integrin-mediated Rac translocation 
in, and the spreading and migration of, OVCAR-3 cells [167]. Thus, the PLD-PA-Rac 
pathway plays an important role in the metastasis of cancer cells, and might provide a 
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connection for integrin and PLD-mediated cancer metastasis [167]. A new mechanism has 
also been suggested for PLD and PA mediated carcinogenesis through Wnt/β-catenin 
signaling network [168]. 
4.2.4. Autotaxin 
The ATX protein is a member of the ectonucleotide pyrophosphatase and phosphodiesterase 
family of enzymes, but unlike other members of this group, ATX possesses 
lysophospholipase D activity. This enzyme hydrolyzes lysophosphatidylcholine (LPC) to 
generate bioactive lipid LPA, which is an important signaling molecule regulates a variety 
of biological process through its receptors. ATX is essential for normal development and is 
implicated in various physiological processes. It also acts as a potent tumor growth factor 
and mitogen that is, associated with pathological conditions such as cancer, pain and 
fibrosis. Exogenous addition of VEGF-A to cultured cells induces ATX expression and 
secretion, resulting in increased extracellular LPA production [169]. This elevated LPA, 
acting through LPA4, modulates VEGF responsiveness by inducing VEGF receptor 2 
expression. Downregulation of ATX secretion in SKOV3 cells significantly attenuates cell 
motility responses to VEGF, ATX, LPA, LPC [169]. Through their respective G protein–
coupled receptors, LPC and LPA have both been reported to stimulate migration [170]. LPC 
was unable to stimulate the cellular migration by itself, ATX had to be present. Knocking 
down ATX secretion, or inhibiting its catalytic activity, blocked cellular migration by 
preventing LPA production and the subsequent activation of LPA receptors [170]. 
5. Summary 
As a combination of central obesity, dyslipidemia, and insulin resistance, MS is the central 
of world–wide prevalence of Type 2 Diabetes Mellitus (T2DM), cardiovascular diseases and 
inflammation. Current animal and clinical evidence strongly suggest that abnormal lipid 
metabolism is closely associated with onset of insulin resistance and cancer. Importantly, 
more and more evidence show that most of the components of the MS are linked in some 
way to the development of various cancers [171-173], although epidemiological studies 
linking the MS to cancer are highly required. Obesity and diabetes have been reported to be 
associated with breast, endometrial, colorectal, pancreatic, hepatic or renal cancer [174, 175]. 
The molecular links between MS and cancer are still unclear, but insulin/insulin-like growth 
factor (IGF) systems and associated intracellular signaling cascades may play an important 
role in mediating MS related cancers [173]. However, the mechanisms by which actually 
promote tumor cell growth in patients with MS need further investigation. Since lipids and 
their metabolites and metabolism pathways are related to metabolic diseases and cancer cell 
growth, we propose that lipids may link to MS and cancers and exploring the related 
molecules and understanding the underlying mechanisms will be helpful in developing 
potential therapies for both MS and cancer. Based on the discoveries of current research 
results, a diet with high amount of oleic acid and balanced ratio of omega-3/omega-6 PUFAs 
would be helpful for health and prevention of both MS and cancer.  
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